CTKB — Cytek Biosciences, Inc.
—
Nasdaq ·
Unknown ·
Unknown ·
CIK 1831915 ·
Last close
$5.70
Market Cap
$745.47M
52W High
$6.34
52W Low
$3.31
ADV30
1,344,721
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 53,229,000 | 31,206,000 | -8,423,000 | -6,097,000 | 446,145,000 | 66,806,000 | 124,791,000 |
| Jun 2026 | 48,140,000 | 28,340,000 | -11,400,000 | -12,158,000 | 446,934,000 | 73,846,000 | 124,980,000 |
| Mar 2026 | 44,135,000 | 21,254,000 | -18,463,000 | -18,866,000 | 449,113,000 | 65,665,000 | 121,469,000 |
| Dec 2025 | 62,141,000 | 32,885,000 | -5,594,000 | -44,076,000 | 461,542,000 | 90,853,000 | 119,803,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-6,591,000
Investing CF
$-23,699,000
Financing CF
$1,379,000
CapEx
$-7,027,000
Dividends Paid
—
Buybacks
$34,000
EPS Diluted TTM
$-0.63
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-138,858,000
Inventory
$52,371,000
Receivables
$60,779,000
ST Investments
$189,093,000
EBIT TTM
$-39,877,000
Pretax Income TTM
$-39,955,000
Interest Exp TTM
$78,000
Analysts
3
Yahoo Snapshot (yfinance, live)
Total Revenue
$207,644,992
EBITDA
$-38,797,000
Free Cash Flow
$8,611,250
Enterprise Value
$531,258,528
Total Cash
$255,899,008
Total Debt
$24,687,000
Shares Out
130,783,967
Trailing EPS
$-0.63
Book Value
$2.46
ROE
-23.2%
ROA
-6.2%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 201,493,000 | -40,384,000 | -66,539,000 | 461,542,000 | 119,803,000 | 341,739,000 | -4,686,000 |
| Dec 2024 | 200,453,000 | -20,523,000 | -6,020,000 | 499,500,000 | 103,763,000 | 395,737,000 | 25,379,000 |
| Dec 2023 | 193,015,000 | -27,845,000 | -12,148,000 | 494,457,000 | 101,393,000 | 393,064,000 | 5,281,000 |
| Dec 2022 | 164,036,000 | -1,804,000 | 2,576,000 | 519,476,000 | 93,930,000 | 425,295,000 | -12,231,000 |
TTM Snapshot
Revenues TTM
$206,709,000
NetIncome TTM
$-80,578,000
OpCashFlow TTM
—
Assets (Latest)
$446,934,000
Forward EPS
$0.07
Max Pain — expiry 2027-04-16 (volume-derived — Yahoo OI feed degraded)
max pain strike: $5.00 · spot: $5.92 · call volume: 6 · put volume: 0
Expected Move to 2027-04-16:
±$4.11
(69.43%) —
implied range
$1.81 –
$10.03
· ATM straddle on $5.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MSSHY | Mitsui-Soko Holdings Co Limited/ADR | $745.80M | $9.97 | — |
| APEI | AMERICAN PUBLIC EDUCATION INC | $745.06M | $40.93 | — |
| EOI | Eaton Vance Enhanced Equity Income Fund | $744.59M | $18.16 | — |
| CPPKF | Faraday Copper Corp. | $741.70M | $2.52 | — |
| MEGI | NYLIM CBRE Global Infrastructure Megatrends Term Fund | $740.64M | $14.23 | — |
News headlines (Yahoo Finance, 1h cache)
Cytek Biosciences to Participate in Upcoming Investor Conferences
2026-11-18 21:30 · Yahoo
Cytek Aurora® Evo System Wins BioTech Breakthrough Award for Drug Discovery Innovation of the Year
2026-11-05 22:00 · Yahoo
Cytek Biosciences (CTKB) Q3 2026 Earnings Call Transcript
2026-11-05 18:29 · Yahoo
Cytek Biosciences, Inc. Q3 2026 Earnings Call Summary
2026-11-05 13:30 · Yahoo
Cytek Biosciences Inc (CTKB) Q3 2026 Earnings Call Highlights: U.S. ...
2026-11-05 05:16 · Yahoo
Cytek Biosciences, Inc. (CTKB) Reports Q3 Loss, Tops Revenue Estimates
2026-11-04 23:45 · Yahoo
Cytek Biosciences Q3 Earnings Call Highlights
2026-11-04 23:14 · Yahoo
Cytek Biosciences Reports Third Quarter 2026 Financial Results
2026-11-04 21:05 · Yahoo
Analysts Estimate Cytek Biosciences, Inc. (CTKB) to Report a Decline in Earnings: What to Look Out for
2026-10-28 13:00 · Yahoo
Cytek Biosciences (CTKB) Stock Sees Modest Fair Value Lift As Analysts Weigh Profitability
2026-10-25 00:14 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.